Literature DB >> 6765962

Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema.

A Agostoni, M Cicardi, G C Martignoni, L Bergamaschini, B Marasini.   

Abstract

Treatment with 17 alpha-methyltestosterone and with some synthetic androgens prevents attacks of hereditary angioedema (HAE). However, the potential hepatotoxicity of 17 alpha-alkylated androgens raises the problem of long-term prophylactic use of these agents. Therefore we compared the efficacy in preventing HAE attacks of 17 alpha-alkylated steroids (danazol and stanozolol) with non-17 alpha-alkylated derivatives (quinbolone, nandrolone decanoate and mesterolone). As the latter group proved ineffective, it seems that a drug's efficacy in preventing HAE attacks is connected to its 17 alpha-alkylation. Moreover, our long-term observations with the minimum effective dose of danazol seem to indicate the absence of important collateral effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6765962     DOI: 10.1016/0091-6749(80)90181-5

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  17 in total

Review 1.  New therapeutics in C1INH deficiency: a review of recent studies and advances.

Authors:  Neil Parikh; Marc A Riedl
Journal:  Curr Allergy Asthma Rep       Date:  2011-08       Impact factor: 4.806

Review 2.  Current management of hereditary angio-oedema (C'1 esterase inhibitor deficiency).

Authors:  A Fay; M Abinun
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

3.  Effect of danazol on dysfunctional C 1 inhibitor in a patient with angioedema.

Authors:  P M Kövary; W Opferkuch; K Echternacht-Happle; R Happle
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

Review 4.  C1 inhibitor deficiency: consensus document.

Authors:  M M Gompels; R J Lock; M Abinun; C A Bethune; G Davies; C Grattan; A C Fay; H J Longhurst; L Morrison; A Price; M Price; D Watters
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

Review 5.  Current and emerging management options for hereditary angioedema in the US.

Authors:  Tolly G Epstein; Jonathan A Bernstein
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema.

Authors:  M D Tarzi; A Hickey; T Förster; M Mohammadi; H J Longhurst
Journal:  Clin Exp Immunol       Date:  2007-07-05       Impact factor: 4.330

7.  Long-term prophylaxis in hereditary angio-oedema: a systematic review.

Authors:  Giorgio Costantino; Giovanni Casazza; Ilaria Bossi; Piergiorgio Duca; Marco Cicardi
Journal:  BMJ Open       Date:  2012-07-11       Impact factor: 2.692

8.  WAO Guideline for the Management of Hereditary Angioedema.

Authors:  Timothy Craig; Emel Aygören-Pürsün; Konrad Bork; Tom Bowen; Henrik Boysen; Henriette Farkas; Anete Grumach; Constance H Katelaris; Richard Lockey; Hilary Longhurst; William Lumry; Markus Magerl; Immaculada Martinez-Saguer; Bruce Ritchie; Alexander Nast; Ruby Pawankar; Bruce Zuraw; Marcus Maurer
Journal:  World Allergy Organ J       Date:  2012-12       Impact factor: 4.084

9.  Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies.

Authors:  Richard G Gower; Paula J Busse; Emel Aygören-Pürsün; Amin J Barakat; Teresa Caballero; Mark Davis-Lorton; Henriette Farkas; David S Hurewitz; Joshua S Jacobs; Douglas T Johnston; William Lumry; Marcus Maurer
Journal:  World Allergy Organ J       Date:  2011-02       Impact factor: 4.084

Review 10.  The Story of Angioedema: from Quincke to Bradykinin.

Authors:  Avner Reshef; Mona Kidon; Iris Leibovich
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.